US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc. Warrant 2026/08/27 11.5C

0.0754

-0.0046-5.75%

Volume:20.33K

Turnover:1.55K

Market Cap:11.94M

PE:-0.34

High:0.0799

Open:0.0799

Low:0.0753

Close:0.0800

52wk High:0.6500

52wk Low:0.0600

Shares:158.37M

Float Shares:158.37M

Volume Ratio:4.88

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2207

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Humacyte, Inc. Warrant 2026/08/27 11.5C

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

- -

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Humacyte, Inc., a clinical-stage biotechnology platform company, develops and manufactures off-the-shelf bioengineered human tissues. The company develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions for complex organ disease. Its Human Acellular Vessel (HAV), a regenerative vascular conduit that is in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company was founded in 2004 and is based in Durham, North Carolina.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/HUMAW/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HUMAW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HUMAW\",,,,,undefined,":{"symbol":"HUMAW","market":"US","secType":"WAR","nameCN":"Humacyte, Inc. Warrant 2026/08/27 11.5C","latestPrice":0.0754,"timestamp":1777469936955,"preClose":0.08,"halted":0,"volume":20326,"delay":0,"changeRate":-0.057500000000000086,"strike":11.5,"lastTradingDate":1787803200000,"nameEN":"Humacyte, Inc. Warrant 2026/08/27 11.5C","floatShares":158372172,"shares":158372172,"eps":-0.2207,"marketStatus":"Trading","change":-0.0046,"latestTime":"04-29 14:20:34 EDT","open":0.0799,"high":0.0799,"low":0.0753,"amount":1547.377728,"amplitude":0.0575,"askPrice":0.095,"askSize":200,"bidPrice":0.0683,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.2207,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1777492800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.08,"volumeRatio":4.880856,"lotSize":1,"type":1,"expireDate":1787803200000,"ul":"HUMA","ulStockBrief":{"symbol":"HUMA","market":"US","secType":"STK","nameCN":"Humacyte, Inc.","latestPrice":0.8192,"timestamp":1777486806666,"preClose":0.8475,"halted":0,"volume":2656514,"delay":0}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HUMAW\",,,,,undefined,":{"symbol":"HUMAW","floatShares":158372172,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.880856,"shares":158372172,"dividePrice":0,"high":0.0799,"amplitude":0.0575,"preClose":0.08,"low":0.0753,"week52Low":0.06,"pbRate":"--","week52High":0.65,"institutionHeld":0,"latestPrice":0.0754,"eps":-0.2207,"divideRate":0,"volume":20326,"delay":0,"ttmEps":-0.2207,"open":0.0799,"prevYearClose":0.0937,"prevWeekClose":0.0868,"prevMonthClose":0.0914,"prevQuarterClose":0.0914,"fiveDayClose":0.0996,"twentyDayClose":0.0914,"sixtyDayClose":0.1315},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HUMAW\",params:#limit:5,,,undefined,":[{"date":"2026-03-27","symbol":"HUMAW","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774598400000,"name":null,"time":"Pre-Market","dateTimestamp":1774584000000,"actualEps":null},{"market":"US","date":"2025-08-11","symbol":"HUMAW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754884800000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HUMAW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HUMAW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"stockEarnings":[{"period":"1week","weight":-0.1304},{"period":"1month","weight":-0.0981},{"period":"3month","weight":-0.3333},{"period":"6month","weight":-0.6432},{"period":"1year","weight":-0.7695},{"period":"ytd","weight":-0.1462}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.1224},{"period":"3month","weight":0.0234},{"period":"6month","weight":0.0469},{"period":"1year","weight":0.292},{"period":"ytd","weight":0.0437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Humacyte, Inc., a clinical-stage biotechnology platform company, develops and manufactures off-the-shelf bioengineered human tissues. The company develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions for complex organ disease. Its Human Acellular Vessel (HAV), a regenerative vascular conduit that is in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company was founded in 2004 and is based in Durham, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.090928},{"month":2,"riseRate":0.5,"avgChangeRate":0.313206},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.164429},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.039243},{"month":5,"riseRate":0.8,"avgChangeRate":0.700607},{"month":6,"riseRate":0.2,"avgChangeRate":-0.228643},{"month":7,"riseRate":0.8,"avgChangeRate":0.371838},{"month":8,"riseRate":0.4,"avgChangeRate":-0.123874},{"month":9,"riseRate":0.4,"avgChangeRate":-0.008618},{"month":10,"riseRate":0.2,"avgChangeRate":-0.139526},{"month":11,"riseRate":0.4,"avgChangeRate":-0.052578},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.18257}],"exchange":"NASDAQ","name":"Humacyte, Inc. Warrant 2026/08/27 11.5C","nameEN":"Humacyte, Inc. Warrant 2026/08/27 11.5C"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"HUMAW\",market:\"US\",,,undefined,":null}}